Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
Tumori ; 106(6): NP63-NP66, 2020 Dec.
Article in English | MEDLINE | ID: mdl-32912066

ABSTRACT

INTRODUCTION: Oligometastatic disease has emerged as an intermediate state between localized and systemic cancer. Improvements in diagnostic modalities such as functional imaging allow a greater frequency of oligometastases diagnosis. Patients with selected oligometastatic epithelial ovarian carcinoma (EOC) may be treated with metastasis-directed stereotactic body radiotherapy (SBRT) rather than chemotherapy. CASE DESCRIPTION: We describe a 58-year-old woman who underwent surgery and chemotherapy for an EOC. The patient underwent 3 chemotherapy lines for recurrence of disease, but had allergic reactions and serious hematologic toxicity. During follow-up, lymph node oligometastases were diagnosed and treated with repeated SBRT because the patient refused further chemotherapy. No side effects were observed after each course of SBRT and the patient obtained complete response of all irradiated sites. CONCLUSIONS: SBRT is a promising treatment approach for recurrent oligometastatic EOC with a high control rate and irrelevant iatrogenic toxicity. The possibility to repeat SBRT courses when new oligometastases are encountered in other sites resulted in an adequate long-term palliation approach.


Subject(s)
Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Palliative Care , Biopsy , Female , Humans , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/radiotherapy , Palliative Care/methods , Positron Emission Tomography Computed Tomography , Radiosurgery/adverse effects , Radiosurgery/methods
3.
Q J Nucl Med Mol Imaging ; 60(4): 397-403, 2016 Dec.
Article in English | MEDLINE | ID: mdl-25017896

ABSTRACT

BACKGROUND: Patients with suspected recurrence of prostate cancer undergoing [18F]fluoromethyl choline ([18F]FCH) PET/CT were retrospectively evaluated to investigate the influence of hormonal therapy (HT) in [18F]FCH uptake. METHODS: [18F]FCH PET/CT was performed in 102 surgically treated patients with suspected recurrence (PSA increase >0.2 ng/mL) of prostate cancer, divided in two groups: under HT (N.=54) and without HT (N.=48) at the time of PET scanning. PET/CT was carried out by an integrated system (Biograph 6, CTI/Siemens, Knoxville, TN, USA) intravenously by administering 4.1 MBq/kg of [18F]FCH to each patient; images were acquired 60 minutes later. RESULTS: On the total number of patients, 66 were found to be true positives (TP), 9 false positives (FP), 5 false negatives (FN) and 22 true negatives (TN), sensitivity to [18F]FCH PET/CT was 93%, specificity 71%, accuracy 86%, positive predictive value (PPV) 88%, negative predictive value (NPV) 81%. In the 54 patients under HT, 38 were TP, 6 FP, 3 FN and 7 TN, sensitivity was 93%, specificity 54%, accuracy 83%, PPV 86% and NPV was 70%. In the 48 patients receiving no HT, 28 were TP, 3 FP, 2 FN and 15 TN, sensitivity was 93%, specificity 83%, accuracy 90%, PPV 90% and NPV 88%. A χ2 test showed that sensitivity, accuracy and PPV did not differ among patients with and without HT, while specificity and NPV were significantly lower (P<0.001) in HT treated patients. CONCLUSIONS: Sensitivity, accuracy and PPV were similar in patients with and without HT. Specificity and NPV were reduced in patients under HT, but further data are necessary to support if this reduction is casual or related to therapy and it could be confirmed in a larger series of patients.


Subject(s)
Choline/analogs & derivatives , Hormones/therapeutic use , Positron-Emission Tomography , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/metabolism , Aged , Aged, 80 and over , Biological Transport/drug effects , Choline/metabolism , Hormones/pharmacology , Humans , Male , Middle Aged , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Recurrence , Retrospective Studies
4.
Tumori ; 101(1): e21-3, 2015 Mar 20.
Article in English | MEDLINE | ID: mdl-25702663

ABSTRACT

Computed tomography and magnetic resonance imaging detected an isolated adrenal lesion in an elderly man with high-risk prostate cancer who was undergoing radiotherapy (RT) and hormonal therapy (HT). When prostate-specific antigen (PSA) was 31.66 ng/mL, the lesion was not identified as a metastasis by 18F-choline positron emission tomography/computed tomography (18F-choline-PET/CT). When PSA was over 100 ng/mL, 18F-choline-PET/CT diagnosed the malignancy. After adrenalectomy, PSA returned to normal, and stable disease remission was obtained. This case suggests that atypical metastasis may be underdiagnosed.


Subject(s)
Adenocarcinoma/diagnosis , Adenocarcinoma/secondary , Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/secondary , Adrenalectomy , Biomarkers, Tumor/blood , Choline/analogs & derivatives , Fluorine Radioisotopes , Positron-Emission Tomography , Prostate-Specific Antigen/blood , Prostatic Neoplasms/pathology , Adenocarcinoma/surgery , Adrenal Gland Neoplasms/surgery , Aged , Antineoplastic Agents, Hormonal/therapeutic use , Chemotherapy, Adjuvant , Humans , Immunohistochemistry , Magnetic Resonance Imaging , Male , Multimodal Imaging/methods , Neoplasms, Second Primary/diagnosis , Positron-Emission Tomography/methods , Prostatic Neoplasms/blood , Prostatic Neoplasms/therapy , Radiotherapy, Adjuvant , Tomography, X-Ray Computed
5.
Rheumatol Int ; 32(5): 1367-70, 2012 May.
Article in English | MEDLINE | ID: mdl-20238219

ABSTRACT

A 62-year-old man presented with a 2-month history of increasing pain in the left hip. Magnetic resonance imaging (MRI) showed bone marrow edema (BME) of the left femur, dual energy X-ray absorptiometry (DXA) showed osteopenia at the same level, whereas pelvis X-rays failed to show any objective findings. After ruling out other possible causes of BME such as aseptic osteonecrosis, infectious arthritis, primary or metastatic malignancy, tuberculosis, osteomyelitis, rheumatoid arthritis, and seronegative spondyloarthropathies, a diagnosis of transient osteoporosis of the hip (TOH) was made, and treatment with teriparatide at a daily dose of 20 µg was started and continued for 4 weeks. Disappearance of the symptoms and normalization of MRI were obtained.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Hip Joint/drug effects , Osteoporosis/drug therapy , Teriparatide/therapeutic use , Absorptiometry, Photon , Arthralgia/etiology , Bone Density/drug effects , Bone Marrow Diseases/etiology , Edema/etiology , Hip Joint/diagnostic imaging , Hip Joint/pathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Multimodal Imaging , Osteoporosis/complications , Osteoporosis/diagnosis , Positron-Emission Tomography , Predictive Value of Tests , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
6.
Eur J Nucl Med Mol Imaging ; 32(9): 1011-7, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15895228

ABSTRACT

PURPOSE: The purpose of this study was to investigate the added value of co-registered fusion imaging using a hybrid system in patients with lymphoma. METHODS: Twenty-four lymphoma patients underwent (67)Ga-SPECT/CT using a hybrid tomograph consisting of a dual-head, variable-angle gamma camera and a low-dose X-ray tube. Results were compared with those of SPECT alone. RESULTS: Forty-five lesions were identified by SPECT alone, while 49 were detected by SPECT/CT. Forty out of the 45 lesions observed on SPECT were confirmed as lymphoma, but five were due to other causes (thoracic aorta blood pool activity, sialoadenitis in the submandibular gland, bowel activity, rib fracture and bone marrow activation due to radiotherapy). SPECT/CT identified nine more neoplastic lesions compared with SPECT alone: four areas of radiopharmaceutical accumulation were observed in para-aortic lymph nodes, three in the spleen, one in the liver and one in para-iliac lymph nodes. In five cases, SPECT/CT provided additional anatomical information over SPECT alone. In four patients, four large areas of (67)Ga uptake (one mediastinal, two supraclavicular and one para-aortic) were better characterised; in one subject uptake was localised in the seventh thoracic vertebra only by SPECT/CT. Hybrid imaging provided additional data in 13 patients (54.2%), thus inducing oncologists to reconsider the therapeutic approach in eight subjects (33.2%): unnecessary treatment was avoided in four (16.6%) while therapy was altered in another four (16.6%). CONCLUSION: SPECT/CT hybrid system is able to provide information not obtained by SPECT alone. It allows the anatomical localisation of lymphoma and physiological radiopharmaceutical uptake, facilitates the diagnosis of tumours located in the abdomen (subdiaphragmatic lesions) and provides information that may cause a change in therapeutic strategy.


Subject(s)
Image Enhancement/methods , Lymphoma/diagnosis , Lymphoma/therapy , Subtraction Technique , Tomography, Emission-Computed, Single-Photon/methods , Tomography, X-Ray Computed/methods , Adolescent , Adult , Citrates , Female , Gallium , Humans , Male , Middle Aged , Prognosis , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...